Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
552 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT03573544 | This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | terminated | Phase 1 / Phase 2 | 54 | OBI Pharma, IncINDUSTRY | 2 | Feb 22, 2024 | clinicaltrials |
| NCT02841540 | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes(Encore-MDS) | terminated | Phase 1 | 127 | Hemavant Sciences GmbHINDUSTRY | 7 | Feb 14, 2024 | clinicaltrials |
| NCT03639194 | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 132 | AbbVieINDUSTRY | 4 | Feb 9, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | unknown | Phase 1 / Phase 2 | 216 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02789345 | A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | completed | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03383692 | Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | completed | Phase 1 | 40 | Daiichi Sankyo Co., Ltd.INDUSTRY | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT03531320 | Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase | completed | Phase 1 / Phase 2 | 19 | InnoPharmax Inc.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04830501 | Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03810742 | Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors | completed | Phase 1 | 44 | PharmaEngineINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04338763 | RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer | unknown | Phase 1 | 48 | Rise Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors(CheckMate358) | completed | Phase 1 / Phase 2 | 578 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 128 | H3 Biomedicine Inc.INDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT04299880 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | completed | Phase 1 | 7 | Sumitomo Pharma America, Inc.INDUSTRY | 4 | Nov 8, 2023 | clinicaltrials |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | completed | Phase 1 | 23 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 3, 2023 | clinicaltrials |
| NCT03780517 | Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | completed | Phase 1 | 117 | Boston PharmaceuticalsINDUSTRY | 7 | Oct 30, 2023 | clinicaltrials |
| NCT05296772 | Phase 1 First-in-human Study of JS014 | unknown | Phase 1 | 60 | Anwita BiosciencesINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05767684 | Neoantigen Derived DCs as Cancer Treatment | unknown | Phase 1 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03808870 | A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer | completed | Phase 1 | 21 | NatureWise Biotech & Medicals CorporationINDUSTRY | 1 | Aug 15, 2023 | clinicaltrials |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 107 | SanofiINDUSTRY | 8 | Jul 10, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | Dracen Pharmaceuticals, Inc.INDUSTRY | 5 | Jun 12, 2023 | clinicaltrials |
| NCT04686383 | Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors | completed | Phase 1 | 17 | Calgent Biotechnology Co., LtdINDUSTRY | 2 | Apr 25, 2023 | clinicaltrials |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT04768868 | The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors(WEE1) | unknown | Phase 1 | 350 | Impact Therapeutics, Inc.INDUSTRY | 3 | Feb 24, 2023 | clinicaltrials |
| NCT01173172 | Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer(BNCT) | completed | Phase 1 / Phase 2 | 17 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02990845 | Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer(PEER) | terminated | Phase 1 / Phase 2 | 16 | National Taiwan University HospitalOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03370302 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies | terminated | Phase 1 | 28 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | completed | Phase 1 | 298 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 11, 2023 | clinicaltrials |
| NCT04336124 | Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients | completed | Phase 1 | 5 | TaiRx, Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03195764 | Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors | terminated | Phase 1 | 21 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 18, 2022 | clinicaltrials |
| NCT03349073 | An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors | completed | Phase 1 | 3 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 18, 2022 | clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT03368196 | DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | completed | Phase 1 | 12 | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT05590650 | A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients | completed | Phase 1 | 21 | China Medical University HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT02310464 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | completed | Phase 1 | 25 | OBI Pharma, IncINDUSTRY | 1 | Oct 3, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | terminated | Phase 1 | 2 | Eden BioCell Ltd.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT05365204 | A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients | unknown | Phase 1 | 24 | National Taiwan University Hospital Hsin-Chu BranchOTHER | 1 | May 9, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials